Abstract【Objective】To investigate the correlation between the expression of mismatch repair (MMR) proteins (MLH1, PMS2, MSH2 and MSH6) and the clinicopathological features and prognosis of endometrial cancer.【Methods】The expression of MMR protein (MLH1, PMS2, MSH2, MSH6) in endometrial cancer tissues was analyzed by immunohistochemistry. The correlation between the expression of MMR protein and the clinicopathological characteristics of patients and the recurrence rate of disease 2 years after operation were compared .【Results】Among 143 cases of endometrial cancer, 39 cases (27.3%) had at least one expression deletion in MLH1, PMS2, MSH2 and MSH6. The expression of MMR protein was significantly correlated with family history, histological grade and vascular invasion of endometrioid adenocarcinoma (P<0.05), but not with age, histological type, FIGO stage, depth of myometrial invasion and lymph node metastasis (P>0.05).The recurrence rate of endometrial cancer patients with loss of MMR protein expression was 17.9% in 2 years after operation, which was not significantly different from that of patients with normal MMR protein expression (19.2%) (P>0.05).【Conclusion】The loss of MMR protein expression in endometrial cancer is significantly correlated with family history, high grade of endometrioid adenocarcinoma and vascular invasion. There is no significant difference in recurrence rate between patients with normal MMR protein expression and patients with deficient MMR protein expression in 2 years. The long-term prognosis needs further follow-up study.
MIN Min,WU Xia. Analysis of Correlation between Mismatch Repair Protein Expression and Clinicopathological Features and Prognosis in Endometrial Cancer[J]. JOURNAL OF CLINICAL RESEARCH, 2019, 36(7): 1249-1251.
[1] Chen W, Zheng R, Baade PD,et al. Cancer statistics in China, 2015[J].CA Cancer J Clin,2016, 66(2):115-132. [2] Kaur S, Lotsari J E, Al-Sohaily S, et al. Identification of subgroup-specific miRNA patterns by epigenetic profiling of sporadic and lynch syndrome-associated colorectal and endometrial carcinoma[J].Clin Epigenetics,2015,7: 20-33. [3] Felsberg J, Thon N, Eigenbrod S, et al. Promoter methylation and expression of mgmt and the DNA mismatch repair genes MLH1, MSH2, MSH 6 and PMS2 in paired primary and recurrent glioblastomas[J].Int J Cancer,2011, 129(3): 659-670. [4] 李惠, 孙怡, 刘春样, 等. MLH1、MSH2、MSH6和PMS2蛋白在结直肠癌中的表达及在Lynch综合征筛查中的意义[J].临床与实验病理学杂志, 2017, 33(4): 360-364. [5] Westin SN, Lacour RA, Urbauer DL, et al. Carcinoma of the lower uterine segment: A newly described association with lynch syndrome[J].J Clin Oncol,2008, 26(36): 5965-5971. [6] Black D, Levine DA, Bogomolniy F,et al. Clinical significance of defective mismatch repair in endometrial carcinoma[J].J Clin Oncol,2005, 23(16): 460-468. [7] Cohn H. New upper bounds on sphere packings II[J].Ann Math,2003, 157(2):689-714. [8] 郭骏辉,刘冬梅,乔爱琪,等. 错配修复蛋白表达与子宫内膜癌临床病理特征的关系[J].肿瘤研究与临床,2017,29(10):649-652.
2019, Vol. 36 
